Tag: Health Care

Displaying 561 - 580 of 938 results.

Pages

Commission approval of final consent order: Following a public comment period, the Commission has approved the issuance of final consent order in the matter concerning Barr Pharmaceuticals, Inc.’s acquisition of PLIVA d.d. The vote to approve the final consent order, copies of which can be found...
A consent order settled charges that Watson Pharmaceuticals, Inc.’s proposed $1.9 billion acquisition of Andrx Corporation, would have likely led to competitive problems in the markets for 13 generic drug products. Watson was required to end its marketing agreements with Interpham...
The Federal Trade Commission today announced its decision to challenge the terms of Watson Pharmaceuticals, Inc.’s proposed $1.9 billion acquisition of Andrx Corporation, a deal that would have led to competitive problems in the markets for 13 generic drug products. In allowing the deal to proceed...
U.S. District Court Judge Colleen Kollar-Kotelly yesterday entered a final order settling the Federal Trade Commission’s charges that drug company Warner Chilcott’s agreement with Barr Laboratories unlawfully delayed entry of Barr’s generic version of Warner Chilcott’s Ovcon birth control pill.
Protecting competition for the sale of prescription drug Ovcon, the Federal Trade Commission today announced that it has agreed to settle its complaint against Warner Chilcott, which manufactures the branded version of the drug. The settlement will result in lower prices for women who use the...
The consent order settles charges that Barr Pharmaceutical, Inc.’s proposed acquisition of Pliva d.d for approximately $2.5 billion would have eliminated current or future competition between Barr and Pliva in certain markets for generic pharmaceuticals treating depression, high...
The Federal Trade Commission today announced its decision to challenge Barr Pharmaceutical, Inc.’s proposed acquisition of Pliva d.d for approximately $2.5 billion. The FTC’s complaint alleges that the acquisition as originally structured would have eliminated current or future competition between...
The consent order settled charges that Thermo Electron Corporation’s proposed $12.8 billion acquisition of Fisher Scientific International, Inc. would harm competition in the U.S. market for high-performance centrifugal vacuum evaporators (CVEs). Thermo and Fisher are the only two...
The Federal Trade Commission today charged that Thermo Electron Corporation’s proposed $12.8 billion acquisition of Fisher Scientific International, Inc. would harm competition in the U.S. market for high-performance centrifugal vacuum evaporators (CVEs) in violation of the antitrust laws.
Commission approval of staff comments to the Virginia House of Delegates: The FTC has approved the filing of comments by the staffs of the Bureaus of Competition and Economics and the Office of Policy Planning with the Virginia House of Delegates on the subject of pharmacy benefit managers (PBMs...
The Federal Trade Commission today told the Senate Judiciary Committee that the agency protects health care consumers from anti-competitive conduct by enforcing antitrust laws, and that the FTC is committed to working with physicians and other providers to give them guidance to avoid antitrust...
The Federal Trade Commission today announced its decision to challenge the conduct of two independent practice associations (IPAs) and 18 member physician practices in the Kansas City area for refusing to deal with health care plans, except on collectively agreed-upon terms, including price. The...
The Commission approved a final consent order settling Commission charges alleging that two independent practice associations (IPAs) and 18 member physician practices in the Kansas City, MO area, refused to deal with health care plans, except on collectively agreed-upon prices and...
The Commission approved a final consent order settling charges alleging that thirty competing association members acted unlawfully by agreeing to set the prices they would charge dental insurance plans, and by refusing to deal with plans that would not accept the collectively...
The Commission approved a final consent order to ensure the maintenance of competition in the market for prone stereotactic breast biopsy systems (SBBSs). The Commission had challenged this merger which was consummated in 2005. The order required the divestiture of all prone SBBS...
Commission approval of final consent order: Following a public comment period, the FTC has approved the issuance of a final consent order in the matter concerning Fresenius AG and Renal Care Group. The Commission vote to issue the final order was 5-0. Copies are available now on the FTC’s Web site...
Staff issues advisory opinion concerning Non-Profit Institutions Act: The staff of the Bureau of Competition has advised Alpena (Michigan) Public Schools that its proposed plan to have pharmaceuticals transferred to it for use by its employees, by the Alpena Regional Medical Center, with actual...
Commission approval of proposed divestitures: The Commission has granted a petition from DaVita Inc. (DaVita) requesting approval of a proposed divestiture related to its recent acquisition of Gambro Healthcare (Gambro). Under the consent order, issued to resolve the competitive problems in the...
The Federal Trade Commission’s Bureau of Competition today issued a summary of agreements filed with the Commission in fiscal year 2005 (ending September 30, 2005) by generic and branded drug manufacturers. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 requires drug...
Commission approval of final consent order: Following a public comment period, the Commission has approved the issuance of a final consent order in the matter concerning Allergan, Inc.’s acquisition of Inamed Corporation. The vote to approve the final order was 4-0, with Commissioner J. Thomas...

Pages